RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-74

The more research I do, the more I agree with SI and the Mesoblast team that want to undertake a subsequent COVID-19 ARDS trial using Remestemcel-L ... look at what the daily death toll average has crept up to as at 11 January - 1.736 people dying each day on average in the USA alone

https://www.nytimes.com/




We are now more than 2 years into this pandemic and the number of people still dying each day is ridiculous IMO ..... many are happy to tout that the current regime of approved drugs and treatments have it all under control .... Really ? Far from it me thinks ...


Are Mesoblast Waiting on the 12 month data in support of the funding request ? The last patient was dosed around the 18th December, 2021 so final assessments would be being tidied up from the last few patients treated by now assuming they survived ....




Both the full 6 month and 12 month data should then be due soon IMO ....


https://www.clinicaltrials.gov/ct2/...atory Distress Syndrome&draw=2&rank=1

MSCs in COVID-19 ARDS


39. Pulmonary symptoms [ Time Frame: 6 months ]
including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization

40. Pulmonary symptoms [ Time Frame: 12 months ]
including the presence of emphysema, COPD, asthma, pulmonary fibrosis, other pulmonary disease, and the need for respiratory support will be reported by randomization